Elizabeth Lynn Kennedy, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 675 Water St, Excelsior, MN 55331 Phone: 952-906-7855 |
Dr. Lucy Kurtz Eikevik, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 675 Water St, Excelsior, MN 55331 Phone: 952-906-7855 |
Joshua Scheck, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 19685 Highway 7, Excelsior, MN 55331 Phone: 952-993-4350 |
Dr. Hilary M Hammell, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 19685 Highway 7, Excelsior, MN 55331 Phone: 952-999-3290 Fax: 952-993-2940 |
Carolyn C Majkrzak, PA-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 470 Water St, Excelsior, MN 55331 Phone: 952-442-6950 |
Swarna Erramreddi Latha, M.D Family Medicine Medicare: Medicare Enrolled Practice Location: 675 Water St, Excelsior, MN 55331 Phone: 952-474-4167 Fax: 952-474-5700 |
Michael T Schulenberg, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 675 Water St, Excelsior, MN 55331 Phone: 952-906-7855 Fax: 952-470-4523 |
News Archive
An international team of transplant physicians has shown that the investigational drug belatacept (LEA29Y) preserves transplanted kidney function as effectively as cyclosporine, the drug most commonly used to prevent the immune system from rejecting transplanted organs.
Pancreatic cancer is expected to surpass breast cancer to become the third leading cause of cancer-related deaths in the United States, according to the latest Cancer Statistics 2016 report, published today by the American Cancer Society in CA: A Cancer Journal for Clinicians.
Urinary incontinence in women is common, with almost 50% of adult women experiencing leakage at least occasionally. Genetic or heritable factors are known to contribute to half of all cases, but until now studies had failed to identify the genetic variants associated with the condition.
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
› Verified 3 days ago